KR20150038363A - 지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르 - Google Patents

지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르 Download PDF

Info

Publication number
KR20150038363A
KR20150038363A KR20157004938A KR20157004938A KR20150038363A KR 20150038363 A KR20150038363 A KR 20150038363A KR 20157004938 A KR20157004938 A KR 20157004938A KR 20157004938 A KR20157004938 A KR 20157004938A KR 20150038363 A KR20150038363 A KR 20150038363A
Authority
KR
South Korea
Prior art keywords
compound
pain
disorder
ring
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR20157004938A
Other languages
English (en)
Korean (ko)
Inventor
줄리안 아담스
마크 엘 벤크
알프레도 씨 카스트로
캐더린 에이 에반스
루이스 그레니어
마이클 제이 그로건
타오 류
다니엘 에이 스나이더
토마스 티 티빗츠
Original Assignee
인피니티 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39323893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150038363(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 인피니티 파마슈티칼스, 인코포레이티드 filed Critical 인피니티 파마슈티칼스, 인코포레이티드
Publication of KR20150038363A publication Critical patent/KR20150038363A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
KR20157004938A 2006-10-10 2007-10-10 지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르 Abandoned KR20150038363A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85052006P 2006-10-10 2006-10-10
US60/850,520 2006-10-10
PCT/US2007/021626 WO2008063300A2 (en) 2006-10-10 2007-10-10 Boronic acids and esters as inhibitors of fatty acid amide hydrolase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097009547A Division KR20090085623A (ko) 2006-10-10 2007-10-10 지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르

Publications (1)

Publication Number Publication Date
KR20150038363A true KR20150038363A (ko) 2015-04-08

Family

ID=39323893

Family Applications (2)

Application Number Title Priority Date Filing Date
KR20157004938A Abandoned KR20150038363A (ko) 2006-10-10 2007-10-10 지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르
KR1020097009547A Abandoned KR20090085623A (ko) 2006-10-10 2007-10-10 지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097009547A Abandoned KR20090085623A (ko) 2006-10-10 2007-10-10 지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르

Country Status (26)

Country Link
US (6) US7947663B2 (https=)
EP (4) EP2399584A1 (https=)
JP (2) JP5641600B2 (https=)
KR (2) KR20150038363A (https=)
CN (2) CN104230971B (https=)
AR (1) AR063165A1 (https=)
AT (1) ATE524188T1 (https=)
AU (1) AU2007322268B2 (https=)
BR (1) BRPI0719218A2 (https=)
CA (1) CA2666224C (https=)
CL (1) CL2007002910A1 (https=)
DK (1) DK2073816T3 (https=)
ES (1) ES2373697T3 (https=)
IL (2) IL197932A (https=)
JO (1) JO3598B1 (https=)
MX (1) MX2009003727A (https=)
NO (1) NO342439B1 (https=)
NZ (1) NZ576851A (https=)
PE (1) PE20081172A1 (https=)
PH (1) PH12012500765A1 (https=)
PT (1) PT2073816E (https=)
RU (1) RU2492174C2 (https=)
SG (3) SG175608A1 (https=)
TW (1) TWI451870B (https=)
UA (1) UA101601C2 (https=)
WO (1) WO2008063300A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
TW201000107A (en) * 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
JP5657566B2 (ja) * 2008-12-24 2015-01-21 バイアル ポルテラ アンド シーエイ エス エイＢＩＡＬ−Ｐｏｒｔｅｌａ ＆ Ｃａ， Ｓ．Ａ． 医薬品
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
CA2757622A1 (en) * 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
AR076687A1 (es) * 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
MX361692B (es) * 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
EP2575823A1 (en) * 2010-05-31 2013-04-10 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. 3-substituted vinylboronates and uses thereof
JP5719028B2 (ja) 2010-10-06 2015-05-13 グラクソスミスクライン エルエルシー Ｐｉ３キナーゼ阻害剤としてのベンズイミダゾール誘導体
WO2012112670A1 (en) * 2011-02-16 2012-08-23 Albert Einstein College Of Medicine Of Yeshiva University Novel lipogenic inhibitors and uses thereof
WO2013049332A1 (en) * 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
AU2013280980B2 (en) 2012-06-25 2017-10-19 Thomas Jefferson University Compositions and methods for treating cancer with aberrant lipogenic signaling
CA2878481A1 (en) * 2012-07-10 2014-01-16 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
CA2887679C (en) * 2012-10-17 2020-12-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for improving glucose uptake
JP2016527193A (ja) * 2013-06-07 2016-09-08 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジン
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
FR3051792B1 (fr) * 2016-05-30 2020-01-24 Ecole Superieure De Physique Et De Chimie Industrielles De La Ville De Paris Nouveaux composes, derives de dioxoborolane ou de dioxaborinane fonctionnalises, leur procede de preparation et leurs utilisations
EP3576747A4 (en) 2017-03-09 2020-12-16 The Penn State Research Foundation SMALL MOLECULES CONTAINING BORON TO INHIBIT THE ACTIVITY OF A RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE
CN108409727A (zh) * 2017-10-25 2018-08-17 巨德峰 一种脂肪酰胺水解酶抑制剂及其制备方法
WO2019173394A1 (en) 2018-03-05 2019-09-12 Wylder Nation Foundation Compositions and methods for activating signaling through the cb1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin
EP3632908A1 (en) * 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
FI3861001T3 (fi) * 2018-10-05 2024-01-03 Pfizer Booria sisältäviä PDE4-inhibiittoreita
MX2021009269A (es) * 2019-02-01 2021-08-24 Univ Leland Stanford Junior Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
JP7598875B2 (ja) * 2019-04-12 2024-12-12 リボサイエンス リミティド ライアビリティ カンパニー エクトヌクレオチドピロホスファターゼホスホジエステラーゼ１阻害剤としての二環式ヘテロアリール誘導体
WO2021071932A1 (en) * 2019-10-07 2021-04-15 Cornell University Antimicrobial and antiviral effects of c2-c7alkyl boronic acids
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
US11395829B2 (en) * 2019-11-21 2022-07-26 Myongji University Industry And Academia Cooperation Foundation Inhibitors of metallo-beta-lactamases produced by multidrug-resistant bacteria
CN112321625A (zh) * 2020-11-30 2021-02-05 河西学院 一种基于叶酸的mida硼酸酯-萘二甲酰亚胺类化合物及其制备与应用
WO2022236278A1 (en) * 2021-05-04 2022-11-10 Sigma-Aldrich Co. Llc Chemically linkable nuclear targeting tags
WO2024155644A2 (en) * 2023-01-18 2024-07-25 Uwm Research Foundation, Inc. Combination therapy for cancer using ros-activated prodrugs and ros-amplifying therapeutics

Family Cites Families (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025A (en) * 1847-03-20 Horatio allen
US6013A (en) * 1849-01-09 Improvement in molding and compressing cores
DE445224C (de) 1924-04-09 1927-06-01 Edward D Feldman Zarge mit abgeschraegten Seitenkanten
US2693688A (en) * 1951-11-23 1954-11-09 Bocchino Ernest Wrist cigarette lighter
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1268808A (en) 1985-07-23 1990-05-08 Alan G. Macdiarmid High capacity polyaniline electrodes
CH671400A5 (https=) 1986-12-17 1989-08-31 Nii Prikladnych
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
DE3807862A1 (de) * 1988-03-10 1989-09-21 Merck Patent Gmbh Smektische fluessigkristallphase
US5273680A (en) 1988-03-10 1993-12-28 Merck Patent Gesellschaft Mit Beschrankter Haftung Fluorinated oligophenyls and their use in liquid crystal materials
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
EP0440082B1 (de) 1990-02-01 1998-04-15 MERCK PATENT GmbH Verfahren zur Umsetzung von fluorierten Aromaten mit Elektrophilen
DE4014488A1 (de) 1990-05-07 1991-11-14 Merck Patent Gmbh Dioxaborinane und fluessigkristallines medium
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
EP0501268B1 (de) * 1991-02-25 1996-06-12 F. Hoffmann-La Roche Ag Flüssigkristalline Verbindungen mit endständigem 1-Alkinylrest
SK120993A3 (en) 1991-04-30 1994-08-10 Procter & Gamble Liquid detergents with an aryl boronic acid
GB2258232B (en) 1991-07-31 1995-03-15 Merck Patent Gmbh Alkoxymethylene fluoroterphenyls and liquid crystalline medium
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
CH683522A5 (de) 1992-03-13 1994-03-31 Hoffmann La Roche Verfahren zur Herstellung von Diarylen.
FR2688783A1 (fr) 1992-03-23 1993-09-24 Rhone Poulenc Chimie Nouveaux borates d'onium ou de complexe organometallique amorceurs cationiques de polymerisation.
FR2688790B1 (fr) 1992-03-23 1994-05-13 Rhone Poulenc Chimie Compositions a base de polyorganosiloxanes a groupements fonctionnels reticulables et leur utilisation pour la realisation de revetements anti-adhesifs.
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
PL167141B1 (pl) 1992-05-12 1995-07-31 Wojskowa Akad Tech Sposób otrzymywania związków ciekłokrystalicznych zawierających pierścień 1,3-dioksa- -2-boranu
JP3255965B2 (ja) 1992-05-26 2002-02-12 昭和シェル石油株式会社 反強誘電性液晶化合物
DE4220065A1 (de) 1992-06-19 1993-12-23 Merck Patent Gmbh Verfahren zur Herstellung von Pyrimidin-Derivaten
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9220189D0 (en) * 1992-09-24 1992-11-04 Central Research Lab Ltd Dioxane derivatives
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
GB9220750D0 (en) * 1992-10-02 1992-11-18 Merck Patent Gmbh Liquid crystalline material forming ananisotropic
DE4236103A1 (de) 1992-10-26 1994-04-28 Hoechst Ag Verfahren zur Kreuzkupplung von aromatischen Boronsäuren mit aromatischen Halogenverbindungen oder Perfluoralkylsulfonaten
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
EP0604289B1 (fr) 1992-12-17 1997-09-24 Valeo Systemes D'essuyage Procédé et dispositif d'alimentation d'un moteur électrique d'entrainement d'un bras d'essuie-glace de véhicule automobile
TW240217B (https=) 1992-12-30 1995-02-11 Glaxo Group Ltd
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
FR2702485B1 (fr) 1993-03-10 1995-04-14 Rhone Poulenc Chimie Compositions à base de polyorganosiloxanes réticulables par voie cationique et leur utilisation dans le domaine de l'antiadhérence papier, de la protection des fibres optiques et des circuits imprimés.
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
GB2278841A (en) * 1993-06-11 1994-12-14 Secr Defence Liquid crystal compounds, mixtures and devices
US5417885A (en) * 1993-08-03 1995-05-23 Showa Shell Sekiyu Kabushiki Kaisha Antiferroelectric liquid crystal compound
US5431842A (en) 1993-11-05 1995-07-11 The Procter & Gamble Company Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
JPH07145174A (ja) 1993-11-22 1995-06-06 Takeda Chem Ind Ltd ジオキサボリナン系化合物、それらの製造方法、該化合物を含む液晶組成物および該組成物を用いた液晶光変調装置
JPH07165717A (ja) 1993-12-16 1995-06-27 Sumitomo Chem Co Ltd 複素環化合物およびその製造法
JPH07206715A (ja) 1994-01-21 1995-08-08 Sumitomo Chem Co Ltd 複素環化合物の製造法
DE19502178A1 (de) 1994-01-27 1995-08-03 Hoechst Ag Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Vorprodukte zur Herstellung von Flüssigkristallen
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5643893A (en) 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
GB2290787B (en) 1994-06-30 1998-10-28 Merck Patent Gmbh Benzene derivatives and a liquid-crystalline medium
JP3702426B2 (ja) 1994-08-03 2005-10-05 関東化学株式会社 トリフルオロメチルベンゼン誘導体および液晶組成物
FR2724660B1 (fr) 1994-09-16 1997-01-31 Rhone Poulenc Chimie Amorceurs de reticulation, par voie cationique, de polymeres a groupements organofonctionnels, compositions a base de polyorganosiloxanes reticulables et contenant ces amorceurs et application desdites compositions en antiadherence
JPH0892137A (ja) 1994-09-26 1996-04-09 Sumitomo Chem Co Ltd 芳香族エステル化合物、その製造法および用途
FR2727416A1 (fr) 1994-11-24 1996-05-31 Rhone Poulenc Chimie Nouveaux amorceurs cationiques thermoactivables, de polymerisation et/ou de reticulation et compositions monomeres et/ou polymeres fonctionnels les mettant en oeuvre
DE4445224B4 (de) 1994-12-17 2014-03-27 Merck Patent Gmbh Benzolderivate
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
KR100423818B1 (ko) * 1995-04-24 2004-07-05 가부시키가이샤 한도오따이 에네루기 켄큐쇼 액정화합물및이를함유하는액정조성물
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
JP3783246B2 (ja) 1995-07-18 2006-06-07 大日本インキ化学工業株式会社 ｐ−テルフェニル誘導体
DE59605843D1 (de) * 1995-07-28 2000-10-12 Rolic Ag Zug Photovernetzbare flüssigkristalline 1,2-Phenylen-Derivate
EP0846670A4 (en) 1995-08-09 1999-01-13 Chisso Corp CYCLOHEXANE DERIVATIVES AND LIQUID CRYSTAL COMPOSITIONS
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
FR2745288B1 (fr) 1996-02-27 1998-04-17 Adir Nouveaux derives de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9605334D0 (en) 1996-03-13 1996-05-15 British Nuclear Fuels Plc Biodecontamination reactor
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
JP3555325B2 (ja) 1996-04-12 2004-08-18 チッソ株式会社 ビアリール誘導体の製造方法
US5892131A (en) * 1997-05-29 1999-04-06 American Cyanamid Company Process for the preparation of pesticidal fluoroolefin compounds
US5998673A (en) 1996-06-03 1999-12-07 American Cyanamid Company 1, 4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents
ZA974582B (en) 1996-06-03 1998-11-26 American Cyanamid Co Process and intermediate compounds for the preparation of pesticidal fluoroolefin compounds
CO4771143A1 (es) 1996-06-03 1999-04-30 Basf Agrochemical Products Bv Agentes insecticidas y acaricidas de 1,4-diaril-2-fluoro-2- buteno y proceso para su preparacion
US5849958A (en) 1997-03-17 1998-12-15 American Cyanamid Company 1,4,diaryl-2-fluoro-2-butene insecticidal and acaricidal agents
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
JPH101450A (ja) * 1996-06-14 1998-01-06 Chisso Corp フッ素置換アルキルエーテル化合物、液晶組成物および液晶表示素子
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH1025261A (ja) 1996-07-09 1998-01-27 Chisso Corp フェノール誘導体の製造方法
KR100338855B1 (ko) 1996-07-31 2002-12-28 시오노기세이야쿠가부시키가이샤 신규 파라테르페닐 화합물
FR2752582B1 (fr) 1996-08-21 2003-06-13 Rhone Poulenc Chimie Compositions a base de polyorganosiloxanes a groupements fonctionnels reticulables et leur utilisation pour la realisation de revetements anti-adherents
JP3899557B2 (ja) 1996-08-21 2007-03-28 大日本インキ化学工業株式会社 フルオロビフェニル誘導体
JP4526605B2 (ja) 1996-08-28 2010-08-18 チッソ株式会社 ラテラルハロゲン置換基を有する４環化合物および液晶組成物
US6177440B1 (en) * 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
JPH10152491A (ja) 1996-11-21 1998-06-09 Dai Ichi Seiyaku Co Ltd 結晶性カルバペネム化合物
EP0959061A4 (en) 1996-11-25 2000-08-23 Chisso Corp 3,3'-DIFLUOROBIPHENYL DERIVATIVES, LIQUID CRYSTAL PREPARATIONS, AND LIQUID CRYSTAL DISPLAY ELEMENTS
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
FR2757530A1 (fr) 1996-12-24 1998-06-26 Rhodia Chimie Sa Utilisation pour la stereophotolithographie - d'une composition liquide photoreticulable par voie cationique comprenant un photoamorceur du type sels d'onium ou de complexes organometalliques
FR2757870B1 (fr) 1996-12-30 1999-03-26 Rhodia Chimie Sa Utilisation de compositions silicones reticulables par voie cationique sous uv et d'un photoamorceur du type borate d'onium, pour le revetements de joints plats, notamment de joints de culasse
FR2758329B1 (fr) 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
FR2758560B1 (fr) 1997-01-20 2000-02-04 Adir Nouveaux derives d'acides aminophenylboronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
JP4098368B2 (ja) 1997-02-13 2008-06-11 チッソ株式会社 ビシクロ〔１．１．１〕ペンタン構造を有する液晶性化合物、液晶組成物及び液晶表示素子
DE19710614A1 (de) 1997-03-14 1998-09-17 Hoechst Ag (1,2,4)-Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE202351T1 (de) * 1997-04-01 2001-07-15 Astrazeneca Ab Pyridinderivate und sie enthaltende pharmazeutische zubereitungen
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
WO1998056392A1 (en) 1997-06-13 1998-12-17 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
TR200002839T2 (tr) * 1998-03-31 2001-01-22 Shionogi & Co., Ltd. 5-Hidroksibenzo[b]tiofen-3-karboksilik asit türevlerinin hazırlanması.
DZ2769A1 (fr) 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
DE19909761A1 (de) 1998-04-17 1999-10-21 Merck Patent Gmbh Benzofuran- und Benzodifuran-Derivate
CA2269561C (en) * 1998-04-22 2007-06-05 Dainippon Ink And Chemicals, Inc. Naphthalene derivative and liquid crystal composition comprising the same
JP2000001463A (ja) 1998-06-12 2000-01-07 Dainippon Ink & Chem Inc ４−シアノベンゼン誘導体の製造方法
GB9814450D0 (en) 1998-07-04 1998-09-02 Sharp Kk Novel compounds
GB2339778A (en) 1998-07-17 2000-02-09 Secr Defence Terphenyl Liquid Crystals
WO2000020466A1 (de) 1998-10-01 2000-04-13 Targor Gmbh Katalysatorsystem
DE19857765A1 (de) 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
DE19858594A1 (de) 1998-12-18 2000-06-21 Merck Patent Gmbh Verfahren zur Herstellung von Cyanbenzolboronsäuren
DE59904576D1 (de) 1998-12-19 2003-04-17 Basell Polyolefine Gmbh Verfahren zur herstellung von mono- oder di-organo-boranen
JP4865129B2 (ja) * 1999-01-13 2012-02-01 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼ阻害剤を設計するための新規の方法
JP4507294B2 (ja) 1999-05-27 2010-07-21 チッソ株式会社 ビアリール誘導体の製造方法
JP2001039975A (ja) 1999-07-26 2001-02-13 Eisai Co Ltd スルホキシド誘導体の結晶およびその製造法
WO2001021606A1 (en) 1999-09-21 2001-03-29 Qinetiq Limited Liquid crystal compounds
US6309406B1 (en) 1999-11-24 2001-10-30 Hamit-Darwin-Fresh, Inc. Apparatus and method for inducing epileptic seizures in test animals for anticonvulsant drug screening
PT1236726E (pt) 1999-12-03 2005-04-29 Ono Pharmaceutical Co Derivados de triazaespiro[5.5]undecano e farmacos que os contem como ingrediente activo
US20030096854A1 (en) 2002-06-12 2003-05-22 Ho-Shen Lin Substituted tricyclics
FR2805273B1 (fr) 2000-02-18 2006-08-11 Rhodia Chimie Sa Traitement de surface de materiau plastique avec une composition a fonctions reactives polymerisable et/ou reticulable
DE10009714A1 (de) 2000-03-01 2001-09-06 Targor Gmbh Verfahren zur Herstellung von Mono- oder Di-organo-boranen
EP1130114A1 (en) * 2000-03-03 2001-09-05 Dr. van Haeringen Laboratorium B.V. Universal variable fragments
GB2362882A (en) 2000-06-02 2001-12-05 Sharp Kk Liquid crystalline optionally laterally fluorinated terphenyl with chiral 3,4-di[(un)saturated-alkoxy]butoxy or 1,4-di[(un)saturated-alkoxy]but-2-oxy terminus
AU2001287399A1 (en) 2000-08-16 2002-02-25 University Of Alberta Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
US6927216B2 (en) * 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
EP1332214B1 (en) * 2000-10-05 2009-11-18 Millenium Pharmaceuticals, Inc. 32144, a human fatty acid amide hydrolase and uses thereof
GB0100110D0 (en) * 2001-01-04 2001-02-14 Univ Leeds Modulation of calcium channel activity
US20040235792A1 (en) * 2001-01-20 2004-11-25 Deadman John J Serine protease inhibitors compromising a hydrogen-bond acceptor
JP4721027B2 (ja) 2001-03-29 2011-07-13 Ｄｉｃ株式会社 フェニルピリミジン誘導体の製造方法
US20030022864A1 (en) * 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7962950B2 (en) * 2001-06-29 2011-06-14 Hewlett-Packard Development Company, L.P. System and method for file system mandatory access control
US6617125B2 (en) 2001-06-29 2003-09-09 Perkinelmer Life Sciences, Inc. Compositions for enhanced catalyzed reporter deposition
US6890940B2 (en) * 2001-06-29 2005-05-10 Kowa Co., Ltd. Bis(2-aryl-5-pyridyl) derivatives
ATE303389T1 (de) 2001-07-09 2005-09-15 Merck Patent Gmbh Thienothiophen-derivate
EP1444981A1 (en) 2001-10-11 2004-08-11 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
US20050090383A1 (en) * 2001-10-12 2005-04-28 Thiele Sven K. Metal complex compositions and their use as catalysts to produce polydienes
ATE360054T1 (de) 2001-11-07 2007-05-15 Merck Patent Gmbh Flüssigkristalline verbindung, flüssigkristallines medium und flüssigkristallanzeige
GB0126844D0 (en) 2001-11-08 2002-01-02 Qinetiq Ltd Novel compounds
WO2003045228A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
WO2003064484A1 (en) 2002-01-28 2003-08-07 Dow Global Technologies Inc. Metal complex compositions based on cobalt and their use as polymerization catalyst for olefins and dienes
DE10206759A1 (de) * 2002-02-19 2003-08-28 Dragoco Gerberding Co Ag Synergistische Mischungen von 1,2-Alkandiolen
DE10211597A1 (de) 2002-03-15 2003-10-02 Merck Patent Gmbh Verfahren zur Herstellung von Ringverbindungen
AU2003223930A1 (en) * 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
JP3852708B2 (ja) 2002-06-27 2006-12-06 アステラス製薬株式会社 アミノアルコール誘導体
US7045652B2 (en) * 2002-07-03 2006-05-16 Pfizer Inc Processes for preparing substituted aryl boronic acids
EP1388538B1 (en) * 2002-07-09 2010-09-01 Merck Patent GmbH Polymerisation Initiator
US20040020447A1 (en) * 2002-08-05 2004-02-05 William Taylor Method and apparatus for advancing air into a fuel reformer by use of an engine vacuum
US20040115475A1 (en) 2002-08-14 2004-06-17 Matsushita Electric Industrial Co., Ltd. Aromatic methylidene compound, methylstyrul compound for producing the same, production electroluminescent element
CA2505361A1 (en) * 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
US20080124275A1 (en) 2002-11-14 2008-05-29 The Scripps Research Institute Crystalline Form of Fatty Acid Amide Hydrolase (Faah)
JP5220264B2 (ja) * 2002-11-27 2013-06-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング テトラヒドロピラン誘導体
US6924269B2 (en) 2002-12-04 2005-08-02 Vdf Futureceuticals, Inc. Enzyme inhibitors and methods therefor
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
ATE409176T1 (de) * 2003-02-21 2008-10-15 Chiesi Farma Spa 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
JP4787150B2 (ja) 2003-03-06 2011-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｊｎｋ阻害剤
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
AU2004220176A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
DE10325438A1 (de) 2003-05-21 2004-12-09 Bayer Cropscience Ag Difluormethylbenzanilide
JP5043428B2 (ja) 2003-06-03 2012-10-10 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリール複素環式化合物ならびにその製造および使用方法
EP1635812A2 (en) * 2003-06-10 2006-03-22 Fulcrum Pharmaceuticals, Inc. Beta-lactamase inhibitors and methods of use thereof
US7017590B2 (en) * 2003-06-10 2006-03-28 Vivienne Joyce Mackinder Microwavable hair curling device
AU2004262524C1 (en) 2003-06-16 2010-08-19 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2004113167A1 (fr) * 2003-06-25 2004-12-29 Valery Ilyich Smetannikov Dispositif de disposition de cargaisons dans un aeronef et de largage de ces cargaisons de l'aeronef
DE10337497A1 (de) 2003-08-14 2005-03-10 Bayer Cropscience Ag 4-Biphenylsubstituierte-Pyrazolidin-3,5-dion-Derivate
WO2005037227A2 (en) 2003-10-16 2005-04-28 Microbia, Inc. Selective cox-2 inhibitors
US20050267071A1 (en) * 2003-10-31 2005-12-01 Fulcrum Pharmaceuticals, Inc. Inhibitors of coronavirus protease and methods of use thereof
AU2004288822A1 (en) * 2003-11-10 2005-05-26 Microbia, Inc. 4-Biarylyl-1-phenylazetidin-2-ones
US20070010559A1 (en) 2003-11-25 2007-01-11 Novo Nordisk A/S Indole derivatives for use as chemical uncoupler
JP2007512263A (ja) * 2003-11-25 2007-05-17 ノボ　ノルディスク　アクティーゼルスカブ 化学的脱共役剤として使用するためのインドール誘導体
JP4491666B2 (ja) 2003-12-02 2010-06-30 東ソー株式会社 フルオレン骨格を有するアリールアミン誘導体の製造方法とその合成中間体
GB2410745B (en) 2004-02-06 2007-07-25 Merck Patent Gmbh Cholestanyl derivatives
UA83416C2 (en) 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Fused ring 4-oxopyrimidine derivative
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
KR200349335Y1 (ko) 2004-02-21 2004-05-06 김노석 절수용 밸브
US7429082B2 (en) * 2004-03-19 2008-09-30 Alfmeier Prazision Ag Baugruppen Und Systemlosungen Vehicle seat with a pivotally installed headrest
EP1781654A1 (en) * 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
TWM265652U (en) * 2004-08-03 2005-05-21 Premier Image Technology Corp Solid integration rod for DLP
DE102004041532A1 (de) 2004-08-27 2006-03-02 Bayer Cropscience Ag Biphenylthiazolcarboxamide
DE102004041530A1 (de) * 2004-08-27 2006-03-02 Bayer Cropscience Ag Biphenylthiazolcarboxamide
US20090005344A1 (en) * 2004-11-01 2009-01-01 Nkuada, Llc Compounds and Methods of Use Thereof
WO2006050236A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
US20080269204A1 (en) * 2004-11-01 2008-10-30 Tatyana Dyakonov Compounds and Methods of Use Thereof
AU2005304318A1 (en) * 2004-11-12 2006-05-18 Trustees Of Tufts College Lipase inhibitors
DE102005023834A1 (de) 2004-11-20 2006-05-24 Bayer Healthcare Ag Substituierte[(Phenylethanoyl)amino]benzamide
US7425281B2 (en) 2004-12-02 2008-09-16 Displaytech, Inc. Liquid crystal compositions comprising an organogermanium compound and methods for using the same
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
ZA200705872B (en) 2005-01-14 2008-09-25 Genelabs Tecnologies Inc Indole derivatives for treating viral infections
US20090005321A1 (en) 2005-02-09 2009-01-01 Microbia, Inc. Phenylazetidinone Derivatives
NZ578297A (en) 2005-02-16 2010-11-26 Anacor Pharmaceuticals Inc Boron-containing small molecules
GB2436766B (en) 2005-02-22 2012-02-08 Sumation Co Ltd High bandgap arylene polymers
US7589066B2 (en) * 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
GB2424881B (en) 2005-04-07 2010-11-24 Merck Patent Gmbh Halophenyl derivatives of bisalkylfluorene
JP4792796B2 (ja) 2005-04-08 2011-10-12 東ソー株式会社 ２，３−ジハロビフェニレン誘導体、その前駆化合物及び製造方法
EP1879860A2 (en) 2005-05-10 2008-01-23 Microbia Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2006124713A2 (en) 2005-05-13 2006-11-23 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
US7674876B2 (en) 2005-05-25 2010-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Synthesis of novel monomers containing the trifluorovinylidene group and the cyanato group and polymers thereof
EP1893562A4 (en) 2005-06-14 2010-04-28 Merck Frosst Canada Ltd REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE-A AND -B
KR100730140B1 (ko) 2005-07-15 2007-06-19 삼성에스디아이 주식회사 트리아진계 화합물 및 이를 이용한 유기 발광 소자
KR100659088B1 (ko) * 2005-07-15 2006-12-21 삼성에스디아이 주식회사 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자
DE102005037925A1 (de) 2005-08-11 2007-02-15 Merck Patent Gmbh Hydro-cyclopenta[a]naphthaline
WO2007028104A2 (en) 2005-09-02 2007-03-08 Auspex Pharmaceuticals, Inc. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
EP1926706B1 (en) 2005-09-13 2012-03-21 Bayer CropScience AG Pesticide bi-phenyl-amidine derivatives
WO2007063012A1 (en) 2005-12-01 2007-06-07 F. Hoffmann-La Roche Ag Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors
US8496835B2 (en) * 2005-12-02 2013-07-30 Sachem, Inc. Anion-exchange displacement chromatography process and anionic organic compounds for use as displacer compounds in anion-exchange displacement chromatography process
EP1976536A4 (en) * 2005-12-30 2011-03-02 Anacor Pharmaceuticals Inc SMALL MOLECULES CONTAINING BORON
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
GB0602046D0 (en) 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
ME02188B (me) 2006-02-16 2016-02-20 Anacor Pharmaceuticals Inc Mali molekuli koji sadrže boron kao antiinflamatorni agensi
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
DE102007009944B4 (de) 2006-03-15 2016-04-28 Merck Patent Gmbh Flüssigkristallines Medium und seine Verwendung
CA2584745A1 (en) 2006-04-13 2007-10-13 Aegera Therapeutics Inc. Use of imidazo(2,1-b) -1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain
JP5145753B2 (ja) 2006-04-20 2013-02-20 Ｊｎｃ株式会社 フルオロイソプロピル基を側鎖として有する化合物およびこれを用いた液晶組成物
RU2008152367A (ru) 2006-06-12 2010-07-20 Анакор Фармасьютикалз, Инк. (Us) Соединения для лечения периодонтального заболевания
US7838542B2 (en) * 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
EP2046769A2 (en) 2006-07-27 2009-04-15 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
JP4881095B2 (ja) * 2006-07-28 2012-02-22 株式会社東海理化電機製作所 キーシステム
US8236783B2 (en) * 2006-08-15 2012-08-07 Duke University ROS-sensitive iron chelators and methods of using the same
WO2008019743A1 (de) 2006-08-16 2008-02-21 Merck Patent Gmbh Cyclohexen-verbindungen für flüssigkristalline mischungen
DE502007004625D1 (de) 2006-09-13 2010-09-16 Merck Patent Gmbh Fluorphenyl-Verbindungen für flüssigkristalline Mischungen
WO2008039827A2 (en) * 2006-09-26 2008-04-03 Aeris Therapeutics, Inc. Polymer systems for lung volume reduction therapy
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
CN101616883B (zh) 2007-01-24 2014-06-18 Jnc株式会社 液晶性化合物、液晶组成物以及液晶显示元件
EP2116522B1 (en) 2007-02-28 2013-09-18 JNC Corporation Pentacyclic liquid crystal compound having cf<sb>2</sb>o bonding group, liquid crystal composition and liquid crystal display
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
WO2008141033A1 (en) 2007-05-08 2008-11-20 Auspex Pharmaceuticals Inc. Substituted naphthalenes
DE102007030269B4 (de) * 2007-06-28 2014-07-17 Mitsubishi Hitachi Power Systems Europe Gmbh Kohlenstaubbrenner zur Verfeuerung von in Dichtstromförderung zugeführtem Brennstoff
WO2009011904A1 (en) 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
EP2287141B1 (en) 2008-05-08 2015-10-21 Sumitomo Chemical Company, Limited Method for producing unsaturated organic compound
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
CA2757622A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.

Also Published As

Publication number Publication date
CN104230971A (zh) 2014-12-24
CL2007002910A1 (es) 2008-07-04
EP2404607A1 (en) 2012-01-11
NO342439B1 (no) 2018-05-22
US8629125B2 (en) 2014-01-14
RU2009113830A (ru) 2010-11-20
EP2399585A1 (en) 2011-12-28
US20110224171A1 (en) 2011-09-15
HK1137137A1 (en) 2010-07-23
US20110230440A1 (en) 2011-09-22
US20090099131A1 (en) 2009-04-16
SG175608A1 (en) 2011-11-28
PE20081172A1 (es) 2008-09-30
EP2399584A1 (en) 2011-12-28
US8349814B2 (en) 2013-01-08
US20150344503A1 (en) 2015-12-03
SG10201908757TA (en) 2019-10-30
PT2073816E (pt) 2011-12-15
MX2009003727A (es) 2009-06-26
NO20091620L (no) 2009-07-09
AR063165A1 (es) 2008-12-30
CA2666224C (en) 2017-07-11
US20130059819A1 (en) 2013-03-07
CN104230971B (zh) 2017-11-24
AU2007322268A1 (en) 2008-05-29
JP2014114305A (ja) 2014-06-26
IL219039A (en) 2015-07-30
NZ576851A (en) 2012-09-28
WO2008063300A3 (en) 2008-07-17
DK2073816T3 (da) 2011-12-12
IL219039A0 (en) 2012-05-31
US9108989B2 (en) 2015-08-18
UA101601C2 (uk) 2013-04-25
TWI451870B (zh) 2014-09-11
TW200820979A (en) 2008-05-16
ATE524188T1 (de) 2011-09-15
EP2073816B1 (en) 2011-09-14
IL197932A0 (en) 2009-12-24
JP5710805B2 (ja) 2015-04-30
US8329675B2 (en) 2012-12-11
WO2008063300A8 (en) 2009-06-11
ES2373697T3 (es) 2012-02-07
KR20090085623A (ko) 2009-08-07
AU2007322268B2 (en) 2013-05-30
PH12012500765A1 (en) 2014-09-08
RU2492174C2 (ru) 2013-09-10
SG10201502266RA (en) 2015-05-28
EP2073816A2 (en) 2009-07-01
JP5641600B2 (ja) 2014-12-17
WO2008063300A2 (en) 2008-05-29
JO3598B1 (ar) 2020-07-05
BRPI0719218A2 (pt) 2014-03-18
US7947663B2 (en) 2011-05-24
IL197932A (en) 2013-11-28
US20140121183A1 (en) 2014-05-01
CA2666224A1 (en) 2008-05-29
JP2010505955A (ja) 2010-02-25
CN101563089A (zh) 2009-10-21

Similar Documents

Publication Publication Date Title
KR20150038363A (ko) 지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르
JP2010505955A5 (https=)
JP5637982B2 (ja) 脂肪酸アミド加水分解酵素の阻害剤
JP2019535759A (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
PT2017314E (pt) Ácidos e ésteres borónicos como inibidores da hidrolase das amidas de ácidos gordos
EP3709998B1 (en) N-[5-(imidazo[1,2-a]pyrimidin-2-yl)phenyl]-benzamide and -benzeneacetamide derivatives as tnf stimulators for the treatment of e.g. infectious diseases and cancer
JP7821573B2 (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
CN121779422A (zh) 作为免疫调节剂的联苯类化合物及其制备方法和应用
US20260028367A1 (en) Dot1l degraders and uses thereof
RU2858130C2 (ru) Бифенильное соединение в качестве иммуномодулятора, способ его получения и его применение
HK1137137B (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
HK1165286A (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
HK1165281A (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150225

Application number text: 1020097009547

Filing date: 20090508

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150327

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150609

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20151225

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160328

Application number text: 1020097009547

Filing date: 20090508

PC1904 Unpaid initial registration fee